Compare SCOR & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | AKTX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 6.5M |
| IPO Year | 2007 | 2014 |
| Metric | SCOR | AKTX |
|---|---|---|
| Price | $6.70 | $3.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | 10.9K | ★ 25.1K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | N/A |
| EPS | ★ 4.25 | N/A |
| Revenue | ★ $403,549,000.00 | N/A |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $7.30 | N/A |
| P/E Ratio | $1.65 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.39 | $0.12 |
| 52 Week High | $10.18 | $6.59 |
| Indicator | SCOR | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 42.12 |
| Support Level | $6.28 | $0.36 |
| Resistance Level | $7.07 | $6.53 |
| Average True Range (ATR) | 0.43 | 0.78 |
| MACD | -0.09 | -0.44 |
| Stochastic Oscillator | 8.08 | 16.22 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.